Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Up 5.2%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report)'s share price shot up 5.2% during trading on Tuesday . The stock traded as high as $29.24 and last traded at $29.13. 225,714 shares were traded during mid-day trading, a decline of 72% from the average session volume of 812,191 shares. The stock had previously closed at $27.70.

Analyst Upgrades and Downgrades

Several research firms have commented on AGIO. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a report on Tuesday. JPMorgan Chase & Co. lowered their price target on Agios Pharmaceuticals from $31.00 to $30.00 and set a "neutral" rating on the stock in a report on Friday, February 23rd. Finally, Royal Bank of Canada lowered their price target on Agios Pharmaceuticals from $43.00 to $42.00 and set an "outperform" rating on the stock in a report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $33.50.

Agios Pharmaceuticals Price Performance

The business has a 50-day moving average of $28.65 and a 200 day moving average of $24.74. The company has a market cap of $1.67 billion, a PE ratio of -4.69 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.72) EPS for the quarter, missing analysts' consensus estimates of ($1.64) by ($0.08). Agios Pharmaceuticals had a negative return on equity of 38.08% and a negative net margin of 1,312.64%. The company had revenue of $7.10 million during the quarter, compared to analysts' expectations of $7.80 million. During the same quarter in the previous year, the company earned $0.67 EPS. The business's quarterly revenue was up 65.1% compared to the same quarter last year. On average, equities analysts predict that Agios Pharmaceuticals, Inc. will post -5.28 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider James William Burns sold 2,642 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the sale, the insider now owns 34,518 shares in the company, valued at $1,124,251.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider James William Burns sold 2,642 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the transaction, the insider now directly owns 34,518 shares of the company's stock, valued at $1,124,251.26. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Brian Goff sold 7,635 shares of the stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $21.64, for a total value of $165,221.40. Following the transaction, the chief executive officer now directly owns 49,436 shares of the company's stock, valued at $1,069,795.04. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,195 shares of company stock worth $735,655. 4.24% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its stake in Agios Pharmaceuticals by 96.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,429 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 700 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in Agios Pharmaceuticals during the second quarter valued at approximately $39,000. Quest Partners LLC bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at approximately $41,000. Tower Research Capital LLC TRC lifted its stake in shares of Agios Pharmaceuticals by 53.5% in the 1st quarter. Tower Research Capital LLC TRC now owns 2,478 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 864 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its stake in shares of Agios Pharmaceuticals by 37.9% in the 1st quarter. Lazard Asset Management LLC now owns 2,930 shares of the biopharmaceutical company's stock valued at $84,000 after purchasing an additional 805 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.